Consonance Capital Management’s AbbVie ABBV Stock Holding History

Consonance Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-833,000	Closed	-$47.6M	–	23
2016 Q1	$47.6M	Buy	833,000 +55,000	+7%	+$3.07M	7.2%	7
2015 Q4	$46.1M	Sell	778,000 -667,900	-46%	-$38.5M	6.18%	9
2015 Q3	$78.7M	Buy	1,445,900 +147,000	+11%	+$9.57M	11.07%	3
2015 Q2	$87.3M	Buy	1,298,900 +121,000	+10%	+$7.9M	8.77%	4
2015 Q1	$69M	Buy	1,177,900 +490,000	+71%	+$29.6M	6.28%	8
2014 Q4	$45M	Buy	687,900 +108,800	+19%	+$6.86M	5.8%	8
2014 Q3	$33.4M	Sell	579,100 -32,200	-5%	-$1.79M	4.59%	9
2014 Q2	$34.5M	Buy	+611,300	New	+$32.1M	5.13%	8

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Consonance Capital Management's ABBV Position: Q2 2016 in Review

Consonance Capital Management sold out of AbbVie (ABBV) in Q2 2016, closing a stake of 833,000 shares — an estimated $47.6M sold.

Consonance Capital Management first reported a position in ABBV in Q2 2014 and held it in 8 quarters. The position peaked at $87.3M in Q2 2015. 1,634 funds tracked by Wall St. Rank hold ABBV as of Q2 2016.

Consonance Capital Management reported no remaining AbbVie position as of Q2 2016 after selling out during the quarter.
Consonance Capital Management sold 833,000 AbbVie shares in Q2 2016, an estimated $47.6M.
Consonance Capital Management first reported a position in AbbVie in Q2 2014 and held it in 8 quarters.
Consonance Capital Management's AbbVie position peaked at $87.3M in Q2 2015.
1,634 funds tracked by Wall St. Rank held AbbVie as of Q2 2016.

Based on Consonance Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.